High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.747
-59.61%
--
--
-1.844
-15.01%
--
--
-1.713
-11.71%
Estimates Revision
The market is revising Downward the revenue expectations for Biohaven Ltd. (BHVN) for FY2025, with the revenue forecasts being adjusted by -14.65% over the past three months. During the same period, the stock price has changed by -48.34%.
Revenue Estimates for FY2025
Revise Downward
-14.65%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.68%
In Past 3 Month
Stock Price
Go Down
-48.34%
In Past 3 Month
12 Analyst Rating
Wall Street analysts forecast BHVN.N stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN.N is 21.30 USD with a low forecast of 9.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.270
Low
9.00
Averages
21.30
High
54.00
Current: 8.270
Low
9.00
Averages
21.30
High
54.00
Citi
Buy
downgrade
$28 -> $14
2025-11-13
New
Reason
Citi
Price Target
$28 -> $14
2025-11-13
New
downgrade
Buy
Reason
Citi lowered the firm's price target on Biohaven to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response letter in spinocerebellar ataxia for the target cut. Citi remains cautious into Biohaven's upcoming Phase 3 depression data but says the recent equity raise alleviates a near-term financing overhang.
BTIG
Buy
downgrade
$33 -> $16
2025-11-06
Reason
BTIG
Price Target
$33 -> $16
2025-11-06
downgrade
Buy
Reason
BTIG lowered the firm's price target on Biohaven to $16 from $33 and keeps a Buy rating on the shares following Tuesday's announcement of the complete response letter for troriluzole in SCA. The CRL likely "ends a messy chapter" for the company in SCA, the analyst tells investors in a research note. The 60% R&D restructuring is hard to model without details, so the calculated $16 TP may be a little low pending a better read on cuts, the firm added.
Piper Sandler
Piper Sandler
Overweight
downgrade
$75 -> $30
2025-11-06
Reason
Piper Sandler
Piper Sandler
Price Target
$75 -> $30
2025-11-06
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Biohaven to $30 from $75 and keeps an Overweight rating on the shares following the FDA's complete response letter for troriluzole in spinocerebellar ataxia, citing RWE and natural history study issues. This follows a complex regulatory history with an initial RTF letter, followed by NDA acceptance in February based on statistical significance benefits from an FDA-guided RWE protocol. Piper views the FDA's decision as a concerning instance of inconsistent guidance.
Bernstein
Outperform -> Market Perform
downgrade
$34 -> $9
2025-11-06
Reason
Bernstein
Price Target
$34 -> $9
2025-11-06
downgrade
Outperform -> Market Perform
Reason
Bernstein downgraded Biohaven to Market Perform from Outperform with a price target of $9, down from $34, following Tuesday's announcement of the complete response letter for troriluzole in SCA. This is a painful downgrade, the firm notes, as Bernstein remains excited about the long-term value of the degrader platform, the original reason for its Outperform rating.
TD Cowen
Ken Cacciatore
Buy
downgrade
$50 -> $15
2025-11-05
Reason
TD Cowen
Ken Cacciatore
Price Target
$50 -> $15
2025-11-05
downgrade
Buy
Reason
TD Cowen analyst Ken Cacciatore lowered the firm's price target on Biohaven to $15 from $50 and keeps a Buy rating on the shares. The firm said the CRL for Vyglxia is highly disappointing, and they are unsure if it will ever make it to market.
BofA
Buy -> Neutral
downgrade
$49 -> $10
2025-11-05
Reason
BofA
Price Target
$49 -> $10
2025-11-05
downgrade
Buy -> Neutral
Reason
BofA downgraded Biohaven to Neutral from Buy with a price target of $10, down from $49, after the company announced that the FDA issued a complete response letter for its troriluzole application for the treatment of spinocerebellar ataxia. The firm believes the pathway forward is "unclear," but says it is also prudent to assume that there is no viable path to market, so it removed troriluzole from its model. The firm trimmed its view of the odds of success for Kv7 by about 20% as today's setback "calls into question the trust-factor on dose interrogation with that agent," the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -1.40, compared to its 5-year average forward P/E of -4.33. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.33
Current PE
-1.40
Overvalued PE
-2.62
Undervalued PE
-6.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.51
Current EV/EBITDA
-2.36
Overvalued EV/EBITDA
-0.66
Undervalued EV/EBITDA
-6.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
67818.60
Current PS
8.30
Overvalued PS
298387.89
Undervalued PS
-162750.70
Financials
Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 3212.46% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 3212.46% over the last month.
Sold
Bought
BHVN.N News & Events
Events Timeline
(ET)
2025-11-12
08:05:12
Biohaven Prices 23.33M Share Spot Secondary Offering at $7.50
2025-11-11 (ET)
2025-11-11
16:20:17
Biohaven Launches $150M Spot Secondary Offering; Price Set Between $7.50 and $8.00
2025-11-11
16:08:22
Biohaven reveals $150M common stock offering
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/f2d56fd9c7d55c947188e352bbf53a1d2c33c9440ea293f1c0e1d6d672bc0a43.jpg)
Preview
5.0
11-17NASDAQ.COMInsider Buying Update for Monday, November 17: BHVN, PRMB
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/e0772aba423105693a5708e671452db84c0154c29d15469cda81ec3c1876d283.png)
Preview
4.0
11-17Yahoo FinanceWilliam Blair Remains Optimistic About Biohaven (BHVN), Anticipates Strong Operational Growth
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/9a7d2d7a307da4aba7e2704a51b236c777527a7bd32adc7794a6b90bd82f5b05.png)
Preview
6.0
11-14BenzingaCitigroup Reiterates Buy Rating on Biohaven, Adjusts Price Target to $14
Sign Up For More News
People Also Watch
FAQ
What is Biohaven Ltd (BHVN.N) stock price today?
What is Biohaven Ltd (BHVN.N)'s business?
What is the price predicton of BHVN.N Stock?
What is Biohaven Ltd (BHVN.N)'s revenue for the last quarter?
What is Biohaven Ltd (BHVN.N)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Biohaven Ltd (BHVN.N)'s fundamentals?
How many employees does Biohaven Ltd (BHVN.N). have?